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Expression of sphingosine kinase-1 (SphK-1) correlates with a poor survival rate of tumor patients. This eﬀect is probably due to
the ability of SphK-1 to be released into the extracellular medium where it catalyzes the biosynthesis of sphingosine-1-phosphate
(S1P), a signaling molecule endowed with profound proangiogenic eﬀects. SphK-1 is a leaderless protein which is secreted by an
unconventional mechanism. In this paper, we will show that in human hepatocarcinoma Sk-Hep1 cells, extracellular signaling is
followed by targeting the enzyme to the cell surface and parallels targeting of FGF-2 to the budding vesicles. We will also show
that SphK-1 is present in a catalitycally active form in vesicles shed by SK-Hep1 and human breast carcinoma 8701-BC cells. The
enzyme substrate sphingosine is present in shed vesicles where it is produced by neutral ceramidase. Shed vesicles are therefore a
site for S1P production in the extracellular medium and conceivably also within host cell following vesicle endocytosis.
1. Introduction
Malignant tumors have the remarkable ability to adapt
their stromal environment to their benefit. They alter the
surrounding extracellular matrix and modify normal cell
behavior to facilitate tumor cell growth, invasion, immune
evasion, and angiogenesis [1].
Most of these eﬀects are mediated by the release of
small vesicles from the tumor cells into the extracellular
medium. Shed vesicles are known to facilitate tumor inva-
sion [2–4], mainly by proteolytic enzymes associated with
their membrane [5–9]. Indeed, the vesicle membranes are
selectively enriched in some components including MMP-
9 [7] and other proteolytic enzymes [4, 6], together with
β1 Integrin and class I HLA molecules [7]. Enrichment of
ganglioside GD3 and caveolin-1 has also been reported [10].
Moreover, vesicles use several mechanisms to contribute to
tumor escape from immune reactions [11–16].
Notably, vesicles carry many proangiogenic growth fac-
tors, expressed diﬀerently depending on the vesicle origin,
and that act on endothelial cells to promote angiogenesis.
Indeed, FGF-2 was detected in vesicles shed by human
hepatocarcinoma Sk-Hep1 cells [17, 18]; VEGF was found
to be present in vesicles shed by human ovarian carcinoma
cells [19] and in vesicles shed by neurons and astrocytes
[20, 21]; angiogenin, IL-6, IL-8, VEGF, and TIMPs were
found in vesicles shed by glioblastoma tumor cells [22].
Additionally, the sphingolipid fraction of vesicles shed
by HT1080 fibrosarcoma and DU-145 human prostate
carcinoma cells also showed proangiogenic activity [23].
Sphingomyelin is a normal component of plasma mem-
branes where it is largely clustered in the outer mem-
brane leaflet. It is subjected to intense metabolism which
is responsible for the formation of a number of bioac-
tive metabolites including ceramide, ceramide-1-phosphate,
sphingosine, and sphingosine-1- phosphate (S1P) [24].
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Ceramide, generated by sphingomyelinase (SMase) action on
spingomyelin, appears to be a critical regulator of cell growth
arrest, diﬀerentiation, and apoptosis [25, 26]. Sphingosine is
formed by ceramide deacylation catalyzed by at least three
diﬀerent isoforms of ceramidase, which diﬀer in optimal pH,
primary structure, and cellular localization [27]. The enzyme
sphingosine kinase (SphK) catalyzes the formation of S1P
from sphingosine and ATP [28]. Two distinct SphK isoforms,
SphK-1 and SphK-2, have been cloned [29, 30]. SphK-1, the
more intensely researched isoform, is primarily localized in
the cytosol, but, following ERK dependent phosphorylation
elicited by various stimuli, it becomes translocated to the
plasma membrane [31]. SphK-1 has been shown to regulate
a wide variety of cellular processes, including the promotion
of cell proliferation, survival, and motility [32] and, just
as importantly, it possesses oncogenic potential [33]. Pre-
vious studies have established that SphK-1, like FGF-2 and
several other proteins, can be released in the extracellular
environment although it lacks a conventional secretory
signal sequence. The mechanism of SphK-1 secretion is
unconventional and likely involves a nonstandard pathway
independent of the endoplasmic reticulum/Golgi system;
the SphK-1 secretion mechanism is only known to require
functional actin dynamics [34]. Notably, the SphK product
S1P, among multiple biological activities, exerts a strong
proangiogenic eﬀect which is known to act synergistically
with growth factors such as FGF-2 [35, 36] and VEGF
[35].
In this study we investigated whether vesicles shed
by hepatocarcinoma and carcinoma cultured cells con-
tain S1P-generating enzymes. The data from this research
demonstrates that neutral ceramidase (nCDase) and SphK-
1 are localized in vesicles, supporting the view that S1P
participates in the proangiogenic activity exerted by these
particles.
2. Materials and Methods
2.1. Cells and Culture Media. Human SK-Hep1 hepatocar-
cinoma cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum (FCS;
Euroclone, Celbio). Human breast carcinoma 8701-BC cells,
kindly provided by Profcessor Minafra [37], were grown in
RPMI 1640 supplemented with 10% fetal calf serum (FCS;
Euroclone, Celbio). Bovine GM7373 fetal aortic endothelial
cells were grown in Eagle’s minimal essential medium
(Euroclone, Celbio) supplemented with 10% FCS, vitamins,
and essential and nonessential amino acids.
2.2. Cell Extraction. Cells were removed from plate by a
scraper and centrifuged at 2000 g for 5 minutes; pelleted cells
were then resuspended in 300 μL of Triton X100 (1%) on
phosphate buﬀer saline (PBS). After 10- minute incubation
at room temperature, the cell extract was centrifuged at 800 g
for 10 minutes The amount of protein extracted from cells
was determined using the Bradford microassay method (Bio-
Rad, Segrate, Milan, Italy) employing bovine serum albumin
(Sigma-Aldrich) as a standard.
2.3. Vesicle Purification from Conditioned Medium. Vesicles
were purified from the conditioned medium as described
above [38]. Briefly, the medium was conditioned by culturing
subconfluent healthy cells for 3 or 24 hours and were cen-
trifuged at 2000 g for 10 minutes and at 4000 g for 15 minutes
The supernatant was ultracentrifuged at 105,000 g in a Ti-60
Rotor (Backman) for 90 minutes Pelleted vesicles were resus-
pended in PBS. The amount of isolated vesicles was deter-
mined by measuring the protein concentration using the
Bradford microassay method (Bio-Rad, Segrate, Milan, Italy)
using bovine serum albumin (Sigma-Aldrich) as a standard.
2.4. Western Blotting. After SDS-PAGE electrophoresis were
cast in 7.5% gels, proteins was blotted onto a nitrocellulose
membrane (Hybond; Amersham Biosciences) that was satu-
rated with 3% nonfat dry milk in Tris Buﬀer Saline 50 mM
pH 7.9/Tween 0.05% (TBS-T). After 5 washes in TBS-
T for 5 minutes each, the nitrocellulose membranes were
incubated overnight at 4◦C, with mouse monoclonal anti-
nCDase antibody 1 : 200 (kindly donated by Professor Ito,
Fukuoka, Japan) [39]. The primary antibody was followed
by peroxidase-conjugated anti-mouse antibodies (1 : 10000)
(Amersham Biosciences) for 1 hour at room temperature.
Immunocomplexes were visualized with the ECL Western
blotting kit (Amersham Biosciences) using Hyperfilm.
2.5. Confocal Immunofluorescence. Cells, seeded at low den-
sity (2.000 cells/well) onto microscope cover slips in 12-
well culture plates (Nunc), were grown overnight in the
complete medium and, when needed, for 3 more days in
a serum-free medium with three medium changes. SphK-1
and SphK-2 were detected by using as primary antibodies,
rabbit polyclonal anti-SphK-1 antibody (kindly donated by
Prof. Obeid, Charleston, SC, USA) [40] 1 : 100, and rabbit
polyclonal anti-SphK-2 antibodies 1 : 100 (kindly provided
by Dr. Nakamura, Kobe, Japan), respectively, [41]. Secondary
antibodies used were antirabbit TRITC-conjugated antibod-
ies (1 : 200 Sigma); β1 Integrin was detected using C27 anti-
β1 Integrin rat primary monoclonal antibody 1 : 150 [42]
and antirat TRITC conjugated secondary antibody (1 : 320,
Sigma). FGF-2 was detected using mouse monoclonal anti-
FGF-2 antibody (0.5 mg/mL 1 : 200, Upstate Biotechnology
type II) and Texas Redconjugated antimouse antibody
(1 : 200, Amersham Biosciences).
In order to stain nuclei, cells were fixed in 3.7% formalde-
hyde and then stained for 10 minutes with propidium iodide
(Sigma).
Immunostained cells were analyzed by confocal micro-
scopy (Olympus 1X70 with Melles Griot laser system).
2.6. Staining of Vesicle Lipids. Vesicle lipids were stained with
the lipophilic styryl compound FM4-64 (Molecular Probes).
Purified vesicles (180μg) were resuspended in 1 ml PBS and
stained with FM4-64 dissolved in PBS without calcium and
magnesium. FM4-64 was added at a final concentration of
5 μg/ml; samples were incubated at room temperature for
15 minutes. Stained vesicles were collected by centrifugation
at 50,000 g for 1 hour, resuspended in 50μl PBS and added to
GM7373 cells to monitor vesicle targeting.
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2.7. Transient Cell Transfection. SK-Hep1 cells were plated in
six-well culture plates at 3 × 105 cells/well and maintained
overnight in high-glucose DMEM containing 10% fetal
calf serum, 2 mM L-glutamine, 100 IU/ml penicillin, and
100 μg/ml streptomycin. The next day, cells were transfected
with SKpeGFP plasmid encoding for SphK-GFP chimera
(kindly donated by Professor Spiegel, Richmond, VA, USA)
[43]. Transfection was carried out using Lipofectamine
Reagent (GIBCO Life Technologies), according to the manu-
facturer’s instructions.
2.8. Sphingosine Kinase Assay. SphK activity was assayed
in isolated vesicles or serum-free conditioned medium as
described by Olivera et al. [28]. Briefly, 50 μg vesicle proteins
were resuspended in 100 μl of the reaction mixture which
contained 20 mM Tris-HCl, pH 7.4, 20% (v/v) glycerol,
1 mM β-mercaptoethanol, 1 mM EDTA, 1 mM sodium
orthovanadate, 15 mM sodium fluoride, protease inhibitors
(10 mg/ml leupeptin,10 mg/ml aprotinin, and 1 mM PMSF),
and 0.5 mM 4-deoxypyridoxine.
The serum-free conditioned medium was concentrated
approximately 40-fold before being employed for enzymatic
activity measurement.
The enzymatic reaction was initiated by adding 50 μM
sphingosine and 1 mM [γ32P] ATP. In some cases, assays
were performed which omitted sphingosine to evaluate the
availability of endogenous sphingosine. After 30- minutes
incubation at 37◦C, the reaction was terminated by adding
20μl 1 N HCl and 900 μl of chloroform/methanol/HCl
(100 : 200 : 1, v/v). Lipids were then extracted, separated
by TLC, labeled SIP and quantified by liquid scintillation
essentially as previously described [44]. Specific activity of
SphK was expressed as pmol of S1P produced/min/mg of
protein.
2.9. Neutral Ceramidase Activity Assay. NCDase activity
was determined using C12-NBD-ceramide as a substrate as
previously described [45]. Briefly, 100 pmol of C12-NBD-
ceramide (NBD-C12:0, d18:1) was incubated for 2 h at
37◦C with an appropriate amount of proteins in 20 μl of
25 mM Tris-HCl buﬀer pH 7.5 and 0.25% (w/v) Triton X-
100. Samples were then applied to a TLC plate, which was
developed with chloroform, methanol, and 25% ammonia
(90 : 20: 0.5, v/v). Spots corresponding to NBD-dodecanoic
acid and C12-NBD-ceramide were scraped, incubated with
methanol at 37◦C to extract the compounds from the silica,
and their fluorescence at 470/525 nm excitation/emission
wavelengths was measured using a Shimadzu 9000 spec-
trophotofluorimeter. The compounds were quantified using
a standard curve of known amounts of C12-NBD-ceramide
and NBD-dodecanoic acid.
3. Results
3.1. Immunolocalization of SphK-1 and Sphk-2 in 8701-
BC and Sk-Hep-1 Cells. In a first group of experiments,
expression and localization of SphK-1 and SphK-2 were
analyzed by immunofluorescence in 8701 BC carcinoma cells
and in Sk-Hep1 hepatocarcinoma cells (Figure 1).
Moreover, since it had been previously demonstrated that
β1 integrin is clustered in shed vesicles [7, 17], distribution
of the two proteins was compared with distribution of β1
integrin.
In both cell lines, the distribution of SphK-2 was quite
diﬀerent from the distribution of β1 integrin (Figures 1(a)
and 1(b) line a). SphK-2 was indeed clustered in the cell
nucleus. However, it was absent in the cell membrane where
instead β1 integrin was located. In contrast, SphK-1 and
β1 integrin appear to colocalize at the plasma membrane
(Figures 1(a) and 1(b) line b). Moreover, as can more
clearly be seen in cells transiently transfected with GFP-
SphK-1 (Figure 2), both SphK-1 and β1 integrin seem to be
more dense in specific areas of the plasma membrane, and
clustering appears to occur in areas of the cell membrane
from which vesicles are released (Figure 2(d)).
3.2. Eﬀects of SerumAddition on SphK-1 Traﬃcking toward the
Cell Periphery. In a previous study, we observed that vesicles
shed by Sk-Hep1 cells mediate FGF-2 release and that vesicle
shedding and release of FGF-2 were simultaneously induced
by the addition of serum to starved cells [17]. By monitoring
intracellular movements of the growth factor subsequent to
serum addition, we showed that within one hour FGF-2
was targeted to the cell periphery and to the cell nucleus
and nucleolus. FGF-2 movements toward the cell periphery
required actin filament integrity [18].
Similarly to FGF-2, SphK-1 is a leaderless protein
secreted by unconventional mechanisms [29, 34] whose
movement toward the cell periphery is mediated by actin
filaments [34]. We therefore theorized that the two proteins
could share a similar export mechanism and we analyzed
whether intracellular movements of SphK-1 were influenced
by serum addition and whether the enzyme colocalized with
FGF-2.
Intracellular distribution of SphK-1 was therefore ana-
lyzed by immunolocalization in starved cells as well as at
time intervals after serum addition and compared with FGF-
2 distribution. As shown in Figure 3, in starved cells the two
proteins did not colocalize. In SphK-1 they were partially
localized in small granules and in FGF-2 they were totally
dispersed.
Thirty minutes after the serum was added both proteins
were clustered in granules and showed a clear colocalization.
One hour after the serum was added large granules contain-
ing both proteins were present near the cell membrane. In
contrast, cell nuclei were exclusively stained by anti-FGF-2
antibodies.
These results suggest that FGF-2 and SphK-1 share a
similar transport mechanism toward the cell periphery and
that the two proteins are both likely to be targeted to the
budding vesicles.
3.3. Detection of an Active Form of SphK-1 in Shed Vesicles.
In order to establish if an active form of SphK-1 is shed
as a component of membrane vesicles, we ascertained
SphK activity in vesicles or cell-conditioned media in some
experiments. Results reported in Table 1 show that SphK-1
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20 μm
(b)
Figure 1: Comparative analysis of β1 Integrin, SphK-2, and SphK-1 immunolocalization. (a) Localization in 8701-BC cells. (b) Localization
in Sk-Hep1 cells. Line a: Immunolocalization of β1 Integrin and SphK-2 showing a diﬀerent distribution of the two molecules. Line b:
Immunolocalization of β1 Integrin and SphK-1. Arrows indicate colocalization areas. β1 Integrin was detected using FITC-conjugated
secondary antibodies and SphK-2 and SphK-1 using Texas red-conjugated secondary antibodies. Arrows indicate colocalization areas.
was clearly detectable in vesicles shed by Sk-Hep1 and 8701-
BC cells, although the activity was found to be greater in
vesicles shed by Sk-Hep1 cells.
SphK-1 activity was also tested in vesicle-deprived con-
ditioned media. No enzymatic activity could be detected in
serum-containing media, even when it was concentrated.
Instead, it was possible to detect a low SphK activity in
40-fold-concentrated serum-free medium that had been
conditioned by maintaining cells in culture for 24 h. As
shown in Table 1, when vesicles were collected from a
medium to which 2M NaCl had been added in order to
solubilize proteoglycans and other molecules unspecifically
Journal of Oncology 5
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Figure 2: Comparative analysis of SphK-1 and of β1 Integrin localization in transfected Sk-Hep1 cells. (a) GFP-bound SphK-1 localization
in transfected cells. The protein is localized in cell membranes where it shows uneven clustering in small spots. (b) Immunolocalization
of β1 Integrin detected using Texas red-conjugated secondary antibodies. β1 Integrin is seen in cell membranes of both transfected and
non-transfected cells. Like SphK-1, β1 Integrin shows uneven clustering in small spots. (c) Double staining shows colocalization of the
two proteins in some areas of the plasma membrane (indicated by arrows). (d) Enlargement of a cell protrusion showing budding areas
(indicated by arrows) in which SphK-1 appears to have a preferential localization.
(a)
(b)
FGF-2 SphK-1 Merge
10 μm
(c)
Figure 3: Course of endogenous SphK-1 and endogenous FGF-2 targeting to the cell periphery over time, observed by immunolocalization
experiments. FGF-2 and SphK-1 immunolocalization at 0, 30, and 60 minutes after serum addition (lines (a), (b), (c), resp.) Sections 3 μm
from surface. FGF-2 was detected using Texas red-conjugated secondary antibodies; SphK-1 was detected using FITC-conjugated antibodies.
Arrows indicate granules of protein localization.
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Table 1: Enzimatic assay of SphK-1 activity.
Sample Incubation mixture with exogenous sphingosine Incubation mixture without exogenous sphingosine
SK-Hep1 vesicles 43.93 pmol/min/mg of protein 26.70 pmol/min/mg of protein
SK-Hep1 vesicles∗ 43.59 pmol/min/mg of protein
SK-Hep1 C.M. 2.23 pmol/min/mg of protein
8701 BC vesicles 14.44 pmol/min/mg of protein 12.61 pmol/min/mg of protein
8701 BC vesicles∗ 16.70 pmol/min/mg of protein
8701 BC CM 2.16 pmol/min/mg of protein
∗
Vesicles recovered from medium in which 2 M NaCl had been added.
Table 2
Sample Enzimatic activity of nCDase
8701 BC cells 2,08 pmol/min/mg of protein
8701 BC vesicles 5,25 pmol/min/mg of protein
bound to the vesicle membrane, the enzymatic activity was
not aﬀected.
The addition of sphingosine increased labeled S1P
production; however, the catalytic activity of the enzyme
was also observed when this substrate was not added. This
result indicates that sphingosine is already present in shed
components of membrane vesicles.
Sphingosine is likely produced by nCDase, which is
known to be localized in plasma membranes and also found
in the extracellular medium [46, 47]. An enzymatically active
form of nCDase was actually found to be present in vesicles
shed by 8701 BC (Figure 4 and Table 2). Moreover, in Sk-
Hep1 cells, we observed colocalization of nCDase and β1
integrin (data not shown), indicating that it is also likely that
nCDase is present in vesicles shed by this cell line.
3.4. Fate of Shed Vesicles. Since S1P can be produced in the
membrane of shed vesicles, the molecule could remain, at
least in part, within the vesicle. Vesicles could adhere to the
plasma membrane of cells surrounding the tumor and S1P
could exert its eﬀects by interacting with receptors localized
at the cell surface. On the other hand, vesicles could be
internalized by the host cell and consequently release S1P
inside cells where it could act as intracellular messenger.
In order to verify these hypotheses, we analyzed the targets
of shed vesicles after adding them to GM7373 cells, an
immortalized line of embryonic bovine aortic endothelial
cells.
For this purpose, vesicles released by Sk-Hep1 cells
were labeled for 15 minutes with the lipid marker FM4-
64. Labeled vesicles were then added to in vitro cultured
GM7373 cells which in turn had been labeled with antibodies
against β1 integrin. As shown in Figure 5, at 10 minutes after
incubation vesicles were observed to be bound to the cell
membrane, while after 20-minutes incubation most vesicles
were internalized and visible in the cytoplasm. At 30 minutes,
the signal borne by lipid marker FM4-64 was no longer
visible, indicating that the lipids of the vesicle membranes
had degraded. In principle therefore, vesicle-associated S1P
Vesicles extract Cell extract
116 kDa
(a)
8701BC vesicles
8701BC cells
0
50
100
150
200
250
300
350
400
450
(b)
Figure 4: Western Blot analysis for nCDase (a) and its densitomet-
ric analisys (b) on 8701BC vesicles and cell extracts.
could act on both membrane receptors and intracellular
targets.
4. Conclusions
Membrane vesicles shed by tumor cells appear to exert a
variety of eﬀects on the surrounding cells. Vesicles are rich
in enzymatic activities able to modify extracellular medium
composition, thus facilitating tumor cell migration and
angiogenesis. Depending on their origin, they also convey
diﬀerent signaling molecules which exert their eﬀects on
lymphocytes, mesenchymal cells, and endothelial cells. Shed
vesicles have been shown to induce angiogenesis using a
variety of mechanisms including the action of proteins such
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Figure 5: Interactions of shed vesicles with endothelial cells. Vesicles shed by SK-Hep1 cells, labelled with lipid styryl dye FM4-64 (red
fluorescence), were added to GM7373 endothelial cells in which β1 Integrin was stained using FITC-conjugated secondary antibodies (green
fluorescence). Cells were incubated with vesicles, respectively, for (a) 10 minutes, (b) 20 minutes, and (c) 30 minutes. The arrows indicate
vesicle localization.
as FGF-2, VEGF, angiogenin, IL-6, IL-8, and TIMPs, and
lipid molecules such as sphingomyelin.
Based on the present results, nCDase and SphK-1 can
now be included among the signaling molecules transferred
by shed membrane vesicles, suggesting that S1P formed at
level of the vesicle membranes plays a role in the biological
processes regulated by these particles.
Interestingly, nCDase, here identified as a component
of shed vesicles, was previously identified in various sub-
cellular compartments such as endosomes, mitochondria,
and microdomains of the plasma membrane [39, 48] but
was also found to be involved in extracellular sphingolipid
metabolism [47]. In this regard it was demonstrated that
although nCDase is localized at the plasma membrane as a
type II integral membrane protein, the enzyme is released
in the extracellular medium after the proteolytic action of
secretases [49, 50]. Moreover, in agreement with the present
results, nCDase, together with acid SMase, was identified as
a component of a complex in the cell membrane domain
which is subjected to budding as well as in conditioned
medium associated with caveolin-1, a key structural protein
of caveole [51] which was also detected in shed vesicles [52].
SphK-1 is a secreted leaderless protein, and the shedding of
membrane vesicles appears to represent a mechanism which
accounts for its secretion. The presence of the enzymatic
protein in shed vesicles does not per se exclude the face
that other mechanisms may also participate in the release of
SphK-1. Indeed it was reported that, in FGF-1 overexpressing
NIH 3T3 cells, SphK-1 is secreted together with FGF-1 as
a component of a high molecular weight complex [53, 54].
However, SphK-1 is also secreted by cells which do not
express FGF-1, and in the absence of stress signaling which
induces FGF-1 secretion. Here we have demonstrated that at
least in some instances SphK-1 is secreted as a component of
shed vesicles. Since shed vesicles also contain nCDase, which
provides the rate-limiting substrate for S1P production by
catalyzing sphingosine generation, it is likely that these
particles cause sustained S1P production.
SphK-1 and S1P produced by its enzymatic activity
are able to mediate a network of paracrine signaling. It is
well known that acting on the two membrane receptors
SIP1 and SIP3, S1P induces morphogenesis in HUVEC cells
[35]. Moreover, since vesicles carry several other molecules
able to aﬀect angiogenesis, the overall eﬀects of vesicles
on surrounding endothelial cells will be amplified and
diﬀerently modulated depending on the specific composition
of the vesicles.
The exact mechanism by which the S1P message borne
by shed vesicles is delivered to the host cell remains to
be explored. Indeed, an attractive hypothesis is that after
interacting with the recipient cell plasma membrane, vesicles
are internalized via endocytosis. SphK-1 and SIP would
therefore be delivered into the cytoplasm of the receiving
cell, where, as already known, SIP could exert its intra-
cellular eﬀects, regulating various processes among which
cell survival is prominent [55, 56]. Indeed vesicles were
shown to convey molecules, such as mRNA and iRNA, to the
cytoplasm of surrounding cells, and it was recently reported
that mRNA included in shed vesicles can be translated in
recipient cells following endocytosis [22].
Alternatively, because SphK-1 association with cell mem-
branes is strengthened by interaction with phosphatidylser-
ine following its phosphorylation [57] and since exposure
of phosphatidylserine on the outer leaflet is a hallmark of
shed membrane vesicles [58, 59], it can also be speculated
that SphK-1, localized in these particles, can generate S1P
in the extracellular environment. If this is the case, the
bioactive lipid generated outside the endothelial cells could
determine key eﬀects on development and proliferation of
endothelial cells, acting as a ligand of S1P1 and/or S1P3
receptors [60, 61]. Independent of the action mechanism,
the ability of shed vesicles to carry on key enzymes for S1P
production which this study brought to light illuminates a
novel aspect of their biochemical properties which is relevant
to a complete understanding of their proangiogenic activity.
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